Russia’s Coronavirus vaccine, Sputnik V, has now drawn praise from the World Health Organization (WHO). India, which has a deal through Dr. Reddy’s Laboratories Ltd with the Russian Direct Investment Fund (RDIF), which would supply 100 million doses of the vaccine, is all geared up to bring relief to its citizens soon.
As per reports, Dr. Reddy’s would hold a trial which would enroll up to 2,000 participations.
Russia has signed preliminary agreements with over 10 countries and received “expressions fo interests” from various others for 1.2 billion doses of its Covid-19 vaccine.
The reports from state media has claimed that the first batch of the Sputnik V vaccine has entered into “civil circulation” in Russia.
Meanwhile Hans Kluge, regional director for Europe of WHO, said the UN health agency greatly appreciates Russia’s efforts, as per Sputnik News.
The Sputnik V, world’s first officially registered vaccine against Covid-19, has been developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology. It presently is undergoing post-registration trials involving nearly 42,000 volunteers.
Kluge, as per reports, is confidence the post-registration trials of the vaccine would be successful. He also thanked all the volunteers who have agreed to submit themselves to clinical testing of the vaccine.
According to the report, Kluge said he is confident that the ongoing post-registration trials of the Sputnik V vaccine will be successful and thanked all the volunteers who agreed to take part in clinical testing of the COVID-19 vaccine.
“Since I have been working in Russia for many years, I know that Russia has a very rich history in the development of vaccines and their production, as well as immunisation”, he added.
On August 11, Russia registered the Sputnik V vaccine. Results of the phase1/2 clinical trials of the Sputnik V vaccine published in the journal The Lancet showed no serious adverse effects and a stable immune response in 100 per cent participants.